TubeRank
LCIDBullmiss
Lucid CityLucid City

Target Price(split-adjusted)

$35.20

Said $3.52· today's shares after the 1-for-10 reverse split (Sep 2025)

352 is going to be the next strong Target so I don't know if that's a able at all today but at least in the next several trading days that should be the next Target@ 5:26 · open at this moment on YouTube ↗

Thesis at the time

Bullish

Lucid Middle East announced a partnership with the Saudi Authority for Accredited Valuers to improve vehicle damage assessments. Saudi Arabia's massive lithium reserve discovery is seen as indirectly strengthening Lucid's AMP2 supply chain. The stock is above all key moving averages and very near overbought on the stochastic RSI. Options show bulls targeting above $4 for January.

Key arguments

  • Saudi Arabia lithium reserve discovery expedites supply chain for AMP2, supporting production ramp to 10K and eventually 150K by 2026
  • Lucid stock up 54% in last month — shorts being squeezed gradually
  • Options consensus for above $4 for January 17, 2025
  • Stock above all key technical indicators — above 50/100/200-day moving averages and Alma

Counter-arguments acknowledged

  • Stochastic RSI at 99.8 — extremely overbought, first sign of weakness could cause volatility
  • Saudi partnership is minor consumer-level improvement, not a major strategic catalyst

The call

Date said
Dec 26, 2024
Deadline
Dec 31, 2024
Price at prediction
$33
Confidence
medium
Specificity
specific

How it resolved

Status
miss
Resolution price
$30.20
Return
-8.5%
Notes
Deadline passed. Only 0% progress toward target $35.2. Price: $30.20.
Why this resolved this way(resolution audit)
Reference price
$33 (anchored at quote date)
Target used
$35.20(split-adjusted from $3.52)
Deadline source
Explicit (extracted from quote)
Effective: Dec 31, 2024
Age at resolution
0.2 months(from publish date)
Resolution snapshot
$30.20 on Dec 31, 2024

Rule that fired

Deadline passed. Only 0% progress toward target $35.2. Price: $30.20.

Full rules: docs/resolution-spec.md.